Levulinic Acid

Levulinic Acid

SCHEMBL27199853

CC(=O)CCC(=O)O.Cc1cncc([C@@H]2CCCN2C)c1C

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
BLM P54132 1/20 0.38
ALOX15 P16050 1/20 0.38
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CHRNA7 P36544 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
CHRNA2 Q15822 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL27199898 0.89 KDM4E (0.43) KDM4EBLMALOX15PRMT5WDR77
Levulinic Acid SCHEMBL31344210 0.85 BLM (0.45) KDM4EBLMALOX15ALDH1A1LMNA
Levulinic Acid SCHEMBL27199934 0.85 BLM (0.45) KDM4EBLMALOX15ALDH1A1LMNA
SCHEMBL31019623 0.83 CHRNB4 (0.46) ALDH1A1LMNACHRNA7TDP1CHRNB2
SCHEMBL27200145 0.83 CHRNB4 (0.46) ALDH1A1LMNACHRNA7TDP1CHRNB2
SCHEMBL30866547 0.83 CHRNB4 (0.46) ALDH1A1LMNACHRNA7TDP1CHRNB2
SCHEMBL11233734 0.83 CHRNB4 (0.46) ALDH1A1LMNACHRNA7TDP1CHRNB2
Citric Acid SCHEMBL27199852 0.82 KDM4E (0.37) KDM4EBLMALOX15PRMT5WDR77
Cadaverine Tartrate SCHEMBL30866583 0.82 BLM (0.57) KDM4EBLMALOX15PRMT5WDR77
L-Lactic Acid SCHEMBL27199862 0.82 BLM (0.48) KDM4EBLMALOX15PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683527-A1 VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF Ready Mix Naturals, LLC (US) 2026-01-28 EP disclosed
US-20250289796-A1 COMPOSITIONS AND METHODS OF USE THEREOF Ready Mix Naturals, LLC (US) 2025-09-18 US disclosed
US-12358888-B2 Vaporizable alkaloid compositions and methods of use thereof Ready Mix Naturals, LLC (US) 2025-07-15 US disclosed
US-12358889-B2 Vaporizable alkaloid compositions and methods of use thereof Ready Mix Naturals, LLC (US) 2025-07-15 US disclosed
CN-118984653-A Vaporizable alkaloid compositions and methods of use thereof 瑞迪美天然有限公司 2024-11-19 CN disclosed
WO-2024155297-A1 VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF Ready Mix Naturals, LLC (US) 2024-07-25 WO disclosed
US-20240246930-A1 VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF Ready Mix Naturals, LLC (US) 2024-07-25 US disclosed
US-11964958-B1 Vaporizable alkaloid compositions and methods of use thereof Ready Mix Naturals, LLC (US) 2024-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246930-A1 VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF SRM, SCLY, SMOX KDM4E 812/4885BLM 3053/4885ALOX15 4144/4885
US-11964958-B1 Vaporizable alkaloid compositions and methods of use thereof SRM, SCLY, SMOX KDM4E 812/4885BLM 3053/4885ALOX15 4144/4885
US-20250289796-A1 COMPOSITIONS AND METHODS OF USE THEREOF OR10J3, TRPA1, TAS2R3 KDM4E 2277/4885BLM 1891/4885ALOX15 712/4885
US-12358888-B2 Vaporizable alkaloid compositions and methods of use thereof SRM, SCLY, SMOX KDM4E 812/4885BLM 3053/4885ALOX15 4144/4885
US-12358889-B2 Vaporizable alkaloid compositions and methods of use thereof SRM, SCLY, SMOX KDM4E 812/4885BLM 3053/4885ALOX15 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.